[1]
|
中国抗癌协会胃癌专业委员会, 中国医师协会外科医师分会上消化道外科医师委员会, 中国人群健康风险管理协作组-胃癌专业组. 中国人群胃癌风险管理公众指南(2023版) [J]. 中华医学杂志, 2023, 103(36): 2837-2849.
|
[2]
|
Macedo, F., Kátia, L., Longatto-Filho, A., et al. (2017) Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission? Journal of Gastric Cancer, 17, 1-10. https://doi.org/10.5230/jgc.2017.17.e1
|
[3]
|
杜京涛, 许新华. 血管内皮生长因子在肿瘤中的研究进展[J]. 肿瘤防治研究, 2009, 36(2): 162-165. https://doi.org/10.3971/J.issn.1000-8578.2009.02.023
|
[4]
|
陈淑慧, 阳帆帆, 何君, 等. 胃癌靶向治疗研究最新进展[J]. 中国临床药理学与治疗学, 2015, 20(8): 950-955.
|
[5]
|
Liu, X., Zheng, Q., Yu, Q., et al. (2020) Apatinib Regulates the Growth of Gastric Cancer Cells by Modulating Apoptosis and Autophagy. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394, 1009-1018.
|
[6]
|
Chen, R., Chen, Q.T. and Dong, Y.H. (2019) Clinical Efficacy of Apatinib in Treating Metastatic Gastric Cancer and Its Effect on IL17. Oncology Letters, 17, 5447-5452. https://doi.org/10.3892/ol.2019.10270
|
[7]
|
Li, J., Qin, S., Xu, J., et al. (2016) Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. Journal of Clinical Oncology, 34, 1448-1454. https://doi.org/10.1200/JCO.2015.63.5995
|
[8]
|
张鹏. 阿帕替尼联合SOX方案对晚期胃癌患者血清 HIF-1α、VEGF及血常规指标的影响[J]. 内蒙古医学杂志, 2023, 55(1): 31-33 37. https://doi.org/10.16096/J.cnki.nmgyxzz.2023.55.01.009
|
[9]
|
Zheng, Y., Yang, X., Shi, H., et al. (2018) A Phase II Trial of Neoadjuvant Therapy Using Apatinib plus SOX Regimen in Locally Advanced Gastric Cancer: Updated Results. Annals of Oncology, 29, 226-227. https://doi.org/10.1093/annonc/mdy282.057
|
[10]
|
王璐, 鲁培, 王朝杰, 等. 阿帕替尼联合SOX方案治疗老年晚期胃癌的临床观察[J]. 河南医学研究, 2018, 27(23): 4245-4247.
|
[11]
|
Xu, J.M., Zhang, Y., Jia, R., et al. (2019) Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study. Clinical Cancer Research, 25, 515-523. https://doi.org/10.1158/1078-0432.CCR-18-2484
|
[12]
|
李元元, 刘海鹏, 沈亦敏, 等. 程序性死亡受体1抑制剂联合化疗在晚期胃癌中的研究进展[J]. 中国临床研究, 2023, 36(9): 1342-1347. https://doi.org/10.13429/j.cnki.cjcr.2023.09.013
|
[13]
|
Kawazoe, A., et al. (2020) Lenvatinib plus Pembrolizumab in Patients with Advanced Gastric Cancer in the First-Line or Second-Line Setting (EPOC1706): An Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1057-1065. https://doi.org/10.1016/S1470-2045(20)30271-0
|
[14]
|
Wang, K.X., Cui, T.Y., Yang, X.D., Wang, G.Q., Jiang, Q.S., Sun, H., et al. (2021) Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial. OncoTargets and Therapy, 14, 4859-4865. https://doi.org/10.2147/OTT.S316288
|
[15]
|
Lee, H.J., Moon, J.Y. and Baek, S.W. (2016) Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer? Journal of Clinical Oncology, 34, 3823-3823. https://doi.org/10.1200/JCO.2016.68.8663
|
[16]
|
秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847.
|
[17]
|
唐琳, 刘波. 阿帕替尼单药或联合其他方式治疗晚期胃癌的临床研究进展[J]. 社区医学杂志, 2022, 20(10): 586-590. https://doi.org/10.19790/j.cnki.JCM.2022.10.13
|
[18]
|
李丽丽, 孟宪萍, 王贵娣, 等. 应用甲磺酸阿帕替尼治疗转移性胃癌患者不良反应的护理[J]. 解放军护理杂志, 2016, 33(23): 64-66.
|
[19]
|
Ren, Z., Zhu, K., Kang, H., et al. (2015) Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients with Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 33, 894-900. https://doi.org/10.1200/JCO.2013.52.9651
|
[20]
|
Zhang, M., Deng, W., Cao, X., et al. (2017) Concurrent Apatinib and Local Radiation Therapy for Advanced Gastric Cancer: A Case Report and Review of the Literature. Medicine, 96, e6241. https://doi.org/10.1097/MD.0000000000006241
|